FDA grants uniQure Regenerative Medicine Advance Therapy (RMAT) Designation
Today we are very happy in the Huntington community. The announcement from Uniqure that the company has received the Regenerative Medicine Advanced Therapy (RMAT) “Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease is more than promising”, says President of IHA, Svein Olaf Olsen. The RMAT ‘licence’ is based on Read more…